Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Eligard® 45 mg

Approved

HHanAll BioPharma Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

CPPActive, not recruiting

CPPApproved

Active, not recruiting

Timeline

Expected Milestones

Q4 2027

ApprovedActive, not recruiting

CPP

NCT06926933

Clinical

Trials by Indication[1]

CPP1 trial

An Open Label, Single-group, Multicenter Study on the Efficacy and Safety of Leuprolide Acetate 45 mg for Injectable Suspension-controlled Release in Subjects With Central (Gonadotropin-dependent) Precocious Puberty

Active, not recruiting·HHanAll BioPharma Co., Ltd.·Approved·NCT06926933·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Eligard® 45 mg. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Eligard® 45 mg. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — HanAll BioPharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: HHanAll BioPharma Co., Ltd.

Related News